GlassScriptPhysician profile
Amit G Shah
NPI 1740288323
$6,936.84
in general payments reported to CMS, 2019-2025
44 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $67.74 · 2021: $300 · 2022: $292 · 2023: $2,506 · 2024: $1,704 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Travel and Lodging: $2,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.84 |
| Travel and Lodging | $2,261.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $1,984.00 | 2023 | |
| Glaxosmithkline, LLC. | $1,534.52 | 2019 | |
| Merck Sharp & Dohme LLC | $1,132.34 | 2020-2024 | |
| Abbvie INC. | $475.52 | 2021-2025 | |
| Novo Nordisk INC | $334.82 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Beigene USA, INC. | $250.51 | 2022-2025 | Brukinsa |
| Smith+Nephew, INC. | $142.38 | 2023 | Real Intelligence |
| Astrazeneca Pharmaceuticals LP | $122.82 | 2020-2025 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $102.79 | 2022 | |
| Amgen INC. | $87.55 | 2025 | Krystexxa, Evenity |
| Abbott Laboratories | $82.71 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $78.73 | 2021-2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $77.65 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Biohaven Pharmaceuticals, INC. | $61.30 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.02 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $34.64 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $30.66 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.64 | 2024 | |
| Mayne Pharma Commercial LLC | $30.09 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.24 | 2019 | |
| Zimmer Biomet Holdings, INC. | $28.68 | 2025 | Persona |
| Esperion Therapeutics, INC. | $28.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.01 | 2024 | Rexulti |
| Exact Sciences Corporation | $23.49 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $21.10 | 2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $20.35 | 2024 | |
| Astellas Pharma US INC | $18.84 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $18.16 | 2025 | Inspire |
| Amarin Pharma, INC. | $17.86 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.30 | 2021 | |
| Bard Peripheral Vascular, INC. | $16.66 | 2023 | Venclose Maven Catheter |
| Corcept Therapeutics | $16.36 | 2025 | Korlym |
| Allergan, INC. | $13.01 | 2020 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.